pre-IPO PHARMA

COMPANY OVERVIEW

Evommune is a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases. We are leveraging our innovative, tissue-based approach to advance insights and accelerate the development of these transformative therapies. Evommune is led by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://evommune.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 27, 2023

Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan


Jun 28, 2023

Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team


Apr 26, 2023

Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases


Oct 3, 2022

Evommune Announces Appointment of Dr. Jeegar Patel as Chief Scientific Officer


Sep 28, 2022

Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis


For More Press Releases


Google Analytics Alternative